Thursday, August 4, 2022

Amgen Buys Chemocentryx For $4 Billion In Cash

Thousand Oaks-based biotech giant Amgen says it is acquiring ChemoCentryx, a publicly traded biopharmaceuticals company which is focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. The company said it will pay $52 per share in cash for ChemoCentryx, with an enterprise value of approximately $3.7 billion. Amgen was advised by PJT Partners, with legal advice from Wachtell, Lipton, Rosen & Katz. ChemoCentryx was advised by Goldman Sachs, with legal advice from Latham & Watkins LLP.